Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.750.06%
QQQ
717.860.15%
BTC/USD
79697.261.9426%
DIA
532.800.24%
GLD
406.450.08%
TLT
82.190.02%

Nautilus Biotechnology Inc

NAUTNASDAQ
Trade with Public
Trade with Public
$0.9049
-0.0146-1.59%
At close: Sep 4, 5:00 PM EST
$0.9050
0.00010.01%
After Hours: 4:07 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Nautilus Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nautilus Biotechnology (NAUT).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

1Buy
1Hold
1Sell
Consensus RatingBuy# Analysts3Avg. Consensus PT$3Upside to Avg. PT+222.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Feb 27, 2026GuggenheimSubbu NambiPT RaiseBuy$3→$4
Dec 5, 2024Goldman SachsMatthew SykesDowngradeNeutral→Sell$2→$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

Guggenheim analyst Subbu Nambi maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Buy and raises the price target from $2.5 to $4.
Benzinga Newsdesk

PRO
Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

Goldman Sachs analyst Matthew Sykes downgrades Nautilus Biotechnology (NASDAQ:NAUT) from Neutral to Sell and lowers the price target from $2.25 to $1.75.
Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

PRO
Jefferies Assumes Nautilus Biotechnology at Hold, Lowers Price Target of $3

Jefferies analyst Tycho Peterson assumes Nautilus Biotechnology (NASDAQ:NAUT) with a Hold rating and lowers Price Target of $3.
Benzinga Newsdesk

PRO
Morgan Stanley Reiterates Equal-Weight on Nautilus Biotechnology, Maintains $6 Price Target

Morgan Stanley analyst Tejas Savant reiterates Nautilus Biotechnology (NASDAQ:NAUT) with a Equal-Weight and maintains $6 price target.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Nautilus Biotechnology, Lowers Price Target to $6

Morgan Stanley analyst Tejas Savant maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Equal-Weight and lowers the price target from $8 to $6.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved